Plain-English translation of NCT06571708 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , an immunotherapy drug, works better when combined with chemotherapy and possibly a second immunotherapy drug called to treat early-stage bladder cancer. Currently, many patients with this type of cancer need surgery to remove their bladder. The study hopes that this medication combination might shrink the cancer enough that patients can keep their bladders and avoid major surgery.
Muscle-invasive bladder cancer is serious and traditionally requires removing the entire bladder, which significantly impacts quality of life. Researchers want to see if this new treatment can shrink tumors enough to preserve the bladder and give patients a better outcome without losing this important organ.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous chemotherapy ( and ) plus immunotherapy over 12 weeks, with clinic visits twice per week. If your cancer responds well, you would continue immunotherapy alone for an additional 39 weeks with fewer clinic visits. Throughout the study, you would have regular scans, blood tests, and a cystoscopy procedure to check how well the treatment is working. The entire treatment course lasts about one year, with recovery periods built in between phases.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States